Joshua Gans' Newsletter • 19 implied HN points • 28 Aug 20
- Widespread frequent testing is crucial to quickly deal with Covid-19 and reduce economic pain. Challenges include the need for cheap, rapid tests and regulators changing their approach for pandemic mitigation.
- The new Abbott test is a $5 fast test authorized by the FDA, but is limited to use on symptomatic individuals. The test requires administration by healthcare providers, impacting its potential impact.
- Regulations can be changed to expand the use of tests like Abbott's which may be more valuable for identifying infectious individuals. The decision to limit the test to symptomatic use may hinder efforts to stop the virus spread.